IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study

Sbianchi, Giulia; Morris, Curly; Iacobelli, Simona; Bosman, Paul; Blaise, Didier; Reményi, Péter; Byrne, Jennifer; Mayer, Jiřı́; Apperley, Jane F.; Lund, Johan; Kobbe, Guido; Isaksson, Cecilia; Lenhoff, Stig; Basak, Grzegorz W.; Touzeau, Cyrille; Wilson, Keith; Muñiz, Soledad González; Scheid, Christof; Browne, Paul; Anagnostopoulos, Αchilles; Jantunen, Esa; Schönland, Stefan; Yakoub‐Agha, Ibrahim; Garderet, Laurent

doi:10.1016/j.clml.2021.05.012

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Přítomnost ≥ 5 % cirkulujících plazmocytů v periferní krvi u pacientů s mnohočetným myelom je prognóza stejně nepříznivá jako při přítomnosti ≥ 20 % plazmocytů v periferní krvi. Proto nově skupina International Myeloma Vzácné typy: MM typu IgM, který je méně často provázen osteolytickými ložisky ve srovnání s typem IgG či IgA (7), MM typu IgD, který je spojen s velmi agresivním chováním a špatnou prognózou (8)(9)(10)(11). Přibližně 1 % až 2 % pacientů má extramedulární ložiska nemoci v době stanovení diagnózy a u 8 % se objeví extramedulární ložiska v průběhu léčby (12).…”

unclassified

Plasma cell neoplasms, multiple myeloma, solitary plasmocytoma a plasma cell leukemia. Clinical symptoms, diagnostic criteria and therapy

Adam¹,

Pour²,

Krejčí³

et al. 2022

Onkologie

View full text Add to dashboard Cite

Plazmocelulární malignity (mnohočetný myelom, solitární Plazmocytom a Plazmocelulární leukemie), Přehled klinických Příznaků, diagnostických kritérií a léčby Working Group definuje PCL přítomností 5 % či více cirkulujících plazmatických buněk detekovatelných při cytologickém hodnocení nátěru periferní krve u pacientů s mnohočetným myelomem. V textu jsou probrány příznaky, diagnostická kritéria a léčba těchto tří chorob spadajících pod skupinové označení plazmocelulární malignity.Klíčová slova: mnohočetný myelom, solitární plazmocytom, plazmocelulární leukemie, daratumumab, transplantace krvetvorné tkáně. Plasma cell neoplasms, multiple myeloma, solitary plasmocytoma a plasma cell leukemia. Clinical symptoms, diagnostic criteria and therapyAccording the WHO classification of malignant hematologic diseases the group plasma cell neoplasms consists of multiple myeloma, solitary plasmocytoma and plasmocytic leukemia. Diagnosis of multiple myeloma requires ≥10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE) namely CRAB (hypercalcemia, renal failure, anemia, or lytic bone lesions) features felt related to the plasma cell disorder, bone marrow clonal plasmacytosis ≥60%, serum involved/uninvolved free light chain (FLC) ratio ≥100 (provided involved FLC is ≥100 mg/L), or >1 focal lesion on magnetic resonance imaging (MRI). The presence of del(17p), t(4;14), t(14;16), t(14;20), gain 1q, or p53 mutation is considered high-risk multiple myeloma. Presence of any two high risk factors is considered double-hit myeloma; three or more high risk factors is triple-hit myeloma. Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt myeloma disease. Before treatment initiation, whole body positron emission tomography-computed tomography or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions. For decades, treatment has been based on radiation, but studies exploring the potential benefit of systemic therapies for high-risk patients are urgently needed, becouse in solitary plasmocytomas of diameter more the 5 cm is the response to radioterapie often incomplete. Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. The presence of ≥5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL by more the 20% ciculating plasma...

show abstract

unclassified